A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy
Jitprapa Konmun, Kwanjit Danwilai, Nuttapong Ngamphaiboon et al. · Medical Oncology · 2017
Cited by 83 works. doi:10.1007/s12032-017-0931-4
Authors
- Jitprapa Konmun
- Kwanjit Danwilai
- Nuttapong Ngamphaiboon
- Bungorn Sripanidkulchai
- Aumkhae Sookprasert
- Suphat Subongkot
References
- The Edmonton Symptom Assessment System (ESAS): A Simple Method for the Assessment of Palliative Care Patients
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
- American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
- Proposal for classifying the acute emetogenicity of cancer chemotherapy.
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
- Zingiberis rhizoma: A comprehensive review on the ginger effect and efficacy profiles
- The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
- Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients
- Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
- Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress